Vaccinium uliginosum L. Improves Amyloid β Protein-Induced Learning and Memory Impairment in Alzheimer's Disease in Mice

Choi, Yoon‐Hee; Kwon, Hyuck-Se; Shin, Suk Pyo; Chung, Cha-Kwon

doi:10.3746/pnf.2014.19.4.343

Cited by 9 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study investigated the neuroprotective effects of EEVC. Despite there being various studies on the effects of V. corymbosum extracts on learning (15,31) and memory (32,33), our study focused on the cognitive changes with regard to aluminium-induced neurodegeneration and haloperidol-induced catalepsy (mechanism of AlCl 3 ). Memory impairment was significant after the exposure of AlCl 3 to the mice, and it induced impaired performance in all the three behavioural parameters, including OFT, Y-Maze test and traction test.…”

Section: Discussionmentioning

confidence: 99%

Neuropharmacological studies of ethanolic extract of Vaccinium corymbosum on Alzheimer’s type dementia and catatonia in Swiss albino mice

Chellammal

Menon

Hasan

et al. 2021

J Herbmed Pharmacol

View full text Add to dashboard Cite

Introduction: Neuroactive herbal drugs enriched with antioxidants are valuable in treating neurocognitive dysfunction and Vaccinium corymbosum, enriched with antioxidant phytochemicals, is used for treating memory disorders. Hence, the present study evaluated the neuroprotective effects of ethanolic extract of Vaccinium corymbosum (EEVC) on aluminium chloride(AlCl3)-induced Alzheimer’s type of dementia and haloperidol-induced catalepsy-associated behavioural changes. Methods:In vitro antioxidant potential was evaluated using 1-diphenyl-2-picrylhydrazyl (DPPH) and 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS). The total phenolic content (TPC) was quantified. For in vivo studies, AlCl3 (100 mg/kg) was orally administered for 42 days, whereas the EEVC was administered on the 21st day until the 42nd day in two doses (200 mg/kg and 400 mg/kg). In the haloperidol-induced group, EEVC was treated for 21 days, and haloperidol (1 mg/kg) was administered to induce behavioural changes. Open-field, Y-Maze and traction tests were performed, and the mice brain acetylcholinesterase (AChE) enzyme was determined. Results: IC50 values in DPPH and ABTS assays were 85.5 μg/mL and 80 μg/mL, respectively and the total phenolic content of EEVC was found to be 0.166 mg. In a behavioral study, animals treated with 200 mg/kg and 400 mg/kg of EEVC exhibited a neuroprotective impact on AlCl3-induced neurodegeneration and haloperidol-induced behavioral changes with significant inhibition (P < 0.05 and P < 0.01, respectively) in acetylcholinesterase enzyme. Conclusion: The neuroprotection by EEVC postulated that it is a promising therapeutic agent for treating behavioral and cognitive dysfunctions. Further investigations on pro-inflammatory cytokine and neuroendocrine regulation in transgenic Alzheimer’s disease (AD)models complement the therapeutic value of V. corymbosum.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuropharmacological studies of ethanolic extract of Vaccinium corymbosum on Alzheimer’s type dementia and catatonia in Swiss albino mice

Chellammal

Menon

Hasan

et al. 2021

J Herbmed Pharmacol

View full text Add to dashboard Cite

show abstract

“…Extract of V. uliginosum partially preserved the outer nuclear layer of retina after light damage [ 19 ]. Another study reported the positive effect of V. uliginosum extract on improving learning and memory impairment in murine Alzheimer’s disease model [ 38 ]. The symptoms of dry eye disease and asthenopia partially overlap [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

The effect of Vaccinium uliginosum extract on tablet computer-induced asthenopia: randomized placebo-controlled study

Park

Lim

et al. 2016

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundTo investigate the alleviation effect of Vaccinium uliginosum extract (DA9301) on tablet computer-induced asthenopia.MethodsThis was a randomized, placebo-controlled, double-blind and parallel study (Trial registration number: 2013–95). A total 60 volunteers were randomized into DA9301 (n = 30) and control (n = 30) groups. The DA9301 group received DA9301 oral pill (1000 mg/day) for 4 weeks and the control group received placebo. Asthenopia was evaluated by administering a questionnaire containing 10 questions (responses were scored on a scales of 0–6; total score: 60) regarding ocular symptoms before (baseline) and 4 weeks after receiving pills (DA9301 or placebo). The participants completed the questionnaire before and after tablet computer (iPad Air, Apple Inc.) watching at each visit. The change in total asthenopia score (TAS) was calculated and compared between the groupsResultsTAS increased significantly after tablet computer watching at baseline in DA9301 group. (from 20.35 to 23.88; p = 0.031) However, after receiving DA9301 for 4 weeks, TAS remained stable after tablet computer watching. In the control group, TAS changes induced by tablet computer watching were not significant both at baseline and at 4 weeks after receiving placebo. Further analysis revealed the scores for “tired eyes” (p = 0.001), “sore/aching eyes” (p = 0.038), “irritated eyes” (p = 0.010), “watery eyes” (p = 0.005), “dry eyes” (p = 0.003), “eye strain” (p = 0.006), “blurred vision” (p = 0.034), and “visual discomfort” (p = 0.018) significantly improved in the DA9301 group.ConclusionsWe found that oral intake of DA9301 (1000 mg/day for 4 weeks) was effective in alleviating asthenopia symptoms induced by tablet computer watching.Trial registrationThe study is registered at www.clinicaltrials.gov (registration number: NCT02641470, date of registration December 30, 2015).

show abstract

“…It is characterized by degeneration of neurons in specific brain regions, mainly the hippocampus. Consequently, leads to a clinical picture of progressive loss of memory and impairments in cognitive functions (Choi et al, 2014).…”

Section: Alzheimermentioning

confidence: 99%

The role of type 2 Diabetes mellitus as a risk factor for Alzheimer's and Parkinson's diseases

Rocha

Goulart

Costa

et al. 2021

RSD

View full text Add to dashboard Cite

Currently, one of the most significant health problems is the increased incidence of obesity and type 2 Diabetes mellitus (DM2). The most recent epidemiological and clinical research studies have indicated that low physical activity, as well as many genetic and environmental factors are the main causes of these metabolic disorders. It is widely recognized that insulin resistance plays a key role in the development of DM2, disrupting not only the functioning of peripheral tissues, but also the brain. Insulin plays a critical role in the central nervous system participating in neuronal survival, neuroplasticity, memory and cognitive functions. In addition, peripheral insulin resistance results in loss of brain function, which indicates a strong relationship between metabolic disorders, cognitive impairment and the emergence of neurodegenerative diseases. There are links between these different pathologies, such as increased oxidative stress, neuroinflammation, changes in glucose metabolism as well as insulin resistance. Advances in the knowledge of these links may contribute to the development of treatments for the prevention of these pathological events. Based on the above, this study aimed to review the mechanisms associated with DM2 in the development of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.

show abstract

Vaccinium uliginosum L. Improves Amyloid β Protein-Induced Learning and Memory Impairment in Alzheimer's Disease in Mice

Cited by 9 publications

References 23 publications

Neuropharmacological studies of ethanolic extract of Vaccinium corymbosum on Alzheimer’s type dementia and catatonia in Swiss albino mice

Neuropharmacological studies of ethanolic extract of Vaccinium corymbosum on Alzheimer’s type dementia and catatonia in Swiss albino mice

The effect of Vaccinium uliginosum extract on tablet computer-induced asthenopia: randomized placebo-controlled study

The role of type 2 Diabetes mellitus as a risk factor for Alzheimer's and Parkinson's diseases

Contact Info

Product

Resources

About